Clearside Biomedical's Asia-Pacific partner, Arctic Vision, has announced that its new drug application for the suprachoroidal use of Arcatus® in treating Uveitic Macular Edema has been accepted in Australia. This exciting development comes as Clearside Biomedical, Inc., a biopharmaceutical company specializing in delivering therapies to the back of the eye through the suprachoroidal space (SCS®), continues to revolutionize treatment options.
Arctic Vision, a specialty ophthalmology company based in China, holds the exclusive license for commercialization and development of XIPERE®, also known as Arcatus, in Greater China, South Korea, Australia, New Zealand, India, and the ASEAN Countries. With this acceptance by the Therapeutic Goods Administration (TGA) of Australia, patients suffering from Uveitic Macular Edema can look forward to a potential breakthrough in their treatment options.